KalVista Pharmaceuticals, Inc. (KALV)
Automate Your Wheel Strategy on KALV
With Tiblio's Option Bot, you can configure your own wheel strategy including KALV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KALV
- Rev/Share 0.0
- Book/Share 1.9212
- PB 7.649
- Debt/Equity 0.0661
- CurrentRatio 5.351
- ROIC -0.9227
- MktCap 734069622.0
- FreeCF/Share -3.0795
- PFCF -4.8008
- PE -3.9775
- Debt/Assets 0.0252
- DivYield 0
- ROE -1.3407
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | KALV | JMP Securities | -- | Mkt Outperform | -- | $19 | Jan. 31, 2025 |
| Initiation | KALV | TD Cowen | -- | Buy | -- | $30 | Jan. 7, 2025 |
| Initiation | KALV | BofA Securities | -- | Buy | -- | $22 | Dec. 18, 2024 |
News
KalVista Pharmaceuticals, Inc. (KALV) Q1 2026 Earnings Call Transcript
Published: September 11, 2025 by: Seeking Alpha
Sentiment: Neutral
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV ) Q1 2026 Earnings Call September 11, 2025 8:30 AM EDT Company Participants Ryan Baker - Head of Investor Relations Benjamin Palleiko - CEO & Director Nicole Sweeny - Chief Commercial Officer Brian Piekos - Chief Financial Officer Paul Audhya - Chief Medical Officer Conference Call Participants Stacy Ku - TD Cowen, Research Division Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Tazeen Ahmad - BofA Securities, Research Division Maurice Raycroft - Jefferies LLC, Research Division Will Soghikian - Leerink Partners LLC, Research Division Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Serge …
Read More
KalVista Pharmaceuticals, Inc. (KALV) Reports Q1 Loss, Lags Revenue Estimates
Published: September 11, 2025 by: Zacks Investment Research
Sentiment: Negative
KalVista Pharmaceuticals, Inc. (KALV) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to a loss of $0.87 per share a year ago.
Read More
KalVista Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2025
Published: August 27, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 10:55 a.m. ET. A live webcast of the presentation will be available on the Company's website at www.kalvista.com. An audio archive will be available on KalVista's website for 30 days following the presentation. About KalVista Pharmaceuticals,.
Read More
KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union
Published: August 11, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) confirmed maintenance of orphan designation for sebetralstat, underscoring the critical unmet need that sebetralstat addresses in the European Union (EU). Sebetralstat, a novel, oral plasma kallikrein inhibitor, has received a positive CHMP opinion for the treatment of acute attacks of.
Read More
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
KalVista jumps 36% in a week after the FDA clears Ekterly, the first oral on-demand therapy for hereditary angioedema.
Read More
KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning
Published: July 08, 2025 by: Seeking Alpha
Sentiment: Positive
FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy, providing a major competitive advantage over injectable options. EKTERLY's convenience and rapid symptom relief position it for strong market adoption, with a $4 billion HAE market opportunity and potential to shift on-demand market share. Global expansion is underway, with seven regulatory submissions, and if approved for these territories, it could increase the amount of revenues that are to be generated.
Read More
KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025
Published: June 05, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of six scientific abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 taking place in Glasgow, United Kingdom from June 13–16, 2025. Details are as follows: Friday, June 13 Potential for Sebetralstat to Address Pseudo-allergic Reaction Burden Secondary to Icatibant in HAE (D1.324): Sally L. Hampton, Paul K. Audhya, Michael D.
Read More
KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new sebetralstat findings related to time to end of progression of hereditary angioedema (HAE) attacks, and the effectiveness of treatment of attacks considered the most debilitating by patients, mucosal attacks, and attacks that have progressed in severity after a treatment delay. These data were presented at two congresses taking place concurrently: the 14th C1-inhibitor Defic.
Read More
About KalVista Pharmaceuticals, Inc. (KALV)
- IPO Date 2015-04-09
- Website https://www.kalvista.com
- Industry Biotechnology
- CEO Benjamin L. Palleiko
- Employees 150